Prognostic value of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and mean platelet volume (MPV) in patients with colorectal carcinoma [Izmir Oncology Group (IZOG) study]

Date

08 Oct 2016

Session

Poster Display

Presenters

utku Oflazoglu

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

U. Oflazoglu1, A. Alacacioglu2, I. Kundak Somali3, M. Yuce4, M.A. Buyruk5, U. Varol1, T. Salman1, H. Taskaynatan1, Y. Yildiz1, Y. Kucukzeybek1, I. Oztop3, M.O. Tarhan3

Author affiliations

  • 1 Medical Oncology, Ataturk Training and Research Hospital,Izmir Katip Celebi University, 35965 - Izmir/TR
  • 2 Medical Oncology, Ataturk Training and Research Hospital,Izmir Katip Celebi University, 35020 - Izmir/TR
  • 3 Medical Oncology, Dokuz Eylul University School of Medicine, Institute of Oncology, 35020 - Izmir/TR
  • 4 Internal Meicine, Ataturk Training and Research Hospital,Izmir Katip Celebi University, 35020 - Izmir/TR
  • 5 Internal Meicine, Dokuz Eylul University Hospital, 35020 - Izmir/TR
More

Resources

Background

Introduction: There are various factors that have been determined to affect recurrence and survival in colorectal cancer (CRC). However, few of them exhibit so high a prognostic marker. The present study aimed to investigate the potential of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and mean platelet volume (MPV) as prognostic markers in patients with CRC.

Methods

We retrospectively examined the demographic and clinical data of 336 patients with colorectal adenocarcinoma in 2008-2014, which recurred after a 12-month follow-up period; the patients had non-metastatic cancer at the time of diagnosis. In order to find out NLR, PLR, and MPV cut-off values, ROC curve analysis was used. Figure 1. ROC Curves of NLR, PLR and MPV for preoperative patients MPV, mean platelet volume; NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; ROC (receiver-operating characteristic.)

Results

Findings: Patients were categorized into two groups according to positive relapse and negative relapse. 89 patients (26.5%) experienced a relapse in the follow-up period. The group NLR≤3.39 had 55.5 months of disease-free survival (p3.39 had 82.8 months (p183 had 78.7 months (p=0.016); the group MPV≤8.3 had 59.7 months, the group MPV>8.3 had 87.2 months; the group MPV>8.3 had 87.2 months and the group MPV

Conclusions

Our study demonstrated that NLR, PLR and MPV levels can actually be relied on as a prognostic factor in patients with CRC. MPV, NLR and PLR values displayed by recently diagnosed patients with CRC may be a reflection of an increased cytokine level and thereby change depending on it.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

Izmir Oncology Group(IZOG) Study

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings